EverSource Wealth Advisors LLC Acquires 131 Shares of Revvity, Inc. (NYSE:RVTY)

EverSource Wealth Advisors LLC raised its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 33.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 522 shares of the company’s stock after acquiring an additional 131 shares during the period. EverSource Wealth Advisors LLC’s holdings in Revvity were worth $58,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of RVTY. EdgePoint Investment Group Inc. grew its position in Revvity by 34.6% during the third quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company’s stock valued at $343,108,000 after acquiring an additional 690,534 shares during the last quarter. Southpoint Capital Advisors LP bought a new position in shares of Revvity in the third quarter worth approximately $25,550,000. Proficio Capital Partners LLC grew its holdings in shares of Revvity by 12,298.3% in the fourth quarter. Proficio Capital Partners LLC now owns 195,769 shares of the company’s stock worth $21,850,000 after purchasing an additional 194,190 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Revvity by 1.7% in the third quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company’s stock worth $809,332,000 after purchasing an additional 108,401 shares during the last quarter. Finally, Holocene Advisors LP grew its holdings in shares of Revvity by 14.6% in the third quarter. Holocene Advisors LP now owns 725,917 shares of the company’s stock worth $92,736,000 after purchasing an additional 92,240 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors.

Revvity Stock Performance

Shares of Revvity stock opened at $109.88 on Thursday. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $13.20 billion, a P/E ratio of 49.72, a P/E/G ratio of 3.82 and a beta of 1.06. The business has a fifty day simple moving average of $116.76 and a two-hundred day simple moving average of $117.74. Revvity, Inc. has a 12 month low of $97.32 and a 12 month high of $129.50.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter last year, the company earned $1.25 earnings per share. On average, equities analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity’s dividend payout ratio is currently 12.67%.

Analyst Upgrades and Downgrades

RVTY has been the topic of several recent analyst reports. Barclays raised their target price on shares of Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Raymond James restated an “outperform” rating and issued a $145.00 target price (up previously from $140.00) on shares of Revvity in a report on Monday, February 3rd. KeyCorp raised their target price on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Sanford C. Bernstein cut shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price on the stock. in a report on Friday, January 10th. Finally, Bank of America upgraded shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 target price on the stock in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $136.25.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 5,492 shares of Revvity stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares of the company’s stock, valued at $2,295,550.12. The trade was a 21.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the transaction, the insider now directly owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.